PAULINIA (SP, Brazil), Nov. 5 /PRNewswire-FirstCall/ -- Alan Reade,
Executive Chairman of Merial Ltd, today inaugurated a new endectocide plant at
Paulinia, Brazil, representing an investment of $US 9m. Merial has invested
$US 25m in its manufacturing plants in Brazil over the past six years.
The inauguration was attended by Mr. Kurt Hausmann, Merial's Vice-
President for Global Manufacturing and Mr. Jorge Sole, Vice-President for
Latin America. Representatives of the Ministry of the Agriculture, Livestock
and Supply, state and federal government officers, Merial customers and animal
health industry representatives were also invited.
The production capacity for the new plant is 150 million doses per year of
IVOMEC(R) Ivomec(R) Gold, and DUOTIN(R) injectable formulations for use in
livestock. An additional 60 jobs will be created at Paulinia to support the
increase in production. "This is the largest animal health plant of its kind
in the Southern Hemisphere", summarizes the Executive Chairman, Alan Reade,
who came to Brazil especially for its inauguration.
The plant was planned and built according to the strict requirements of
the Food and Drug Administration (FDA) to enable exports to the USA and
incorporates the highest levels of safety and environmental requirements. When
approved by the FDA, this will be the first plant producing animal health
products in Brazil able to export to the United States.
"With the new plant, Merial Brazil becomes a global supplier of cattle
endectocides to other Merial subsidiaries," states Jorge Sole. The Brazilian
affiliate currently exports, among other products, IVOMEC(R) Gold, -- a unique
injectable long acting endectocide formulation for use in cattle -- to Latin
America, South Africa and, in the near future, to Australia, New Zealand and
"It is the most modern plant for Merial animal health products worldwide,"
emphasizes Kurt Hausmann.
Merial is a world leading innovation-driven animal health company,
providing a comprehensive range of products to enhance the health, well-being
and performance of a wide range of animals. Merial employs around 6,000 people
and operates in more than 150 countries world-wide. Its 2002 sales were in
excess of $1.7 billion.
Merial is a joint venture between Merck & Co., Inc. (NYSE: MRK) and
Aventis S.A. (NYSE: AVE). For further information please see www.merial.com